TRENTON, N.J. (AP) - Pfizer Inc. spent $3.55 million in the second quarter lobbying the federal government on multiple patent issues, implementation of the 2010 healthcare overhaul and drug shortage issues, according to a quarterly disclosure report.

That was 55 percent more than the $2.3 million the New York-based company spent on lobbying a year earlier and $3.8 million in this year's first quarter.

Pfizer, the world's biggest drugmaker by revenue, lobbied on bills to overhaul patent laws and to prohibit marketing of generic drugs authorized by the maker of the brand-name version, according to the report it filed July 19 with the House clerk's office. Pfizer has a deal authorizing another company to begin selling a generic version of its blockbuster cholesterol drug Lipitor, which brought in nearly $11 billion last year, after Lipitor's U.S. patent expires on Nov. 30. Pfizer will keep a good part of the revenue from the authorized generic, as sales of brand-name Lipitor plunge and other generic companies begin producing the pill.

Also the maker of impotence pill Viagra and smoking cessation treatment Chantix, Pfizer lobbied on bills that would combat counterfeit medicines, address the shortage of widely used hospital drugs and allow reimportation of drugs from countries with cheaper prices. Pfizer lobbied for incentives for developing new antibiotics; it sells two for very serious infections, Zosyn and Zyvox.

It lobbied on several issues related to implementation of the 2009 health care overhaul, including negotiation of prices for drugs purchased through Medicare and a bill that would eliminate the independent payment advisory board, which is designed to hold down spending.

Pfizer lobbied on a free-trade agreement with Korea and on market access and regulatory issues involving multiple countries. It also lobbied on the fee the government charges to review and approve experimental drugs.

Pfizer lobbied concerning funding for several federal departments and agencies, including the Food and Drug Administration and National Institutes of Health.

Besides Congress and the White House, the company lobbied the FDA, Internal Revenue Service, Health Resources & Services Administration, Patent & Trademark Office, Centers for Medicare and Medicaid Services, National Security Council and the Departments of Commerce, State, Treasury and Health & Human Services, according to a disclosure report filed July 19 with the House clerk's office.

A federal law enacted in 1995 requires lobbyists to disclose activities that could influence members of the executive and legislative branches.

Date: September 30, 2011
Source: Associated Press